You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
|
|---|---|
| Published in |
Molecular Cancer Research, March 2021
|
| DOI | 10.1158/1541-7786.mcr-20-0751 |
| Pubmed ID | |
| Authors |
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, Alexander Y Andreev-Drakhlin, Funda Meric-Bernstam, Aung Naing, Sarina Piha-Paul, Janku Filip, Shubham Pant, Timothy A Yap, David S Hong, Siqing Fu, Daniel Karp, Erick Campbell, Hung Le, Matthew T Campbell, Amishi Y Shah, Nizar M Tannir, Arlene O Siefker-Radtke, Jianjun Gao, Jason Roszik, Vivek Subbiah |
X Demographics
The data shown below were collected from the profiles of 125 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 45 | 36% |
| India | 6 | 5% |
| France | 4 | 3% |
| Brazil | 4 | 3% |
| Spain | 4 | 3% |
| Germany | 3 | 2% |
| Turkey | 3 | 2% |
| China | 2 | 2% |
| Mexico | 2 | 2% |
| Other | 14 | 11% |
| Unknown | 38 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 58 | 46% |
| Scientists | 35 | 28% |
| Practitioners (doctors, other healthcare professionals) | 26 | 21% |
| Science communicators (journalists, bloggers, editors) | 5 | 4% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 30% |
| Student > Master | 3 | 11% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 2 | 7% |
| Professor | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 10 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Agricultural and Biological Sciences | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Economics, Econometrics and Finance | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 10 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 67. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2023.
All research outputs
#650,338
of 25,734,859 outputs
Outputs from Molecular Cancer Research
#28
of 2,127 outputs
Outputs of similar age
#18,939
of 454,780 outputs
Outputs of similar age from Molecular Cancer Research
#2
of 68 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,127 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,780 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.